Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
15 November, 2018 03:23 IST
Glenmark Pharma gets USFDA acceptance for new drug Ryaltris
Source: IRIS | 08 Aug, 2018, 09.47AM
Comments  |  Post Comment

Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the company's New Drug Application for its leading respiratory pipeline candidate Ryaltris (rye-al' - tris), an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older. Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, has been conditionally accepted by the FDA as the brand name.

''We are pleased that Glenmark's rigorous study of Ryaltris led to today's filing acceptance by the FDA,'' said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. (Q,N,C,F)* ''We look forward to offering a potential new treatment option for people suffering from seasonal allergic rhinitis.''

The filing for Ryaltris includes efficacy and safety results from two pivotal, randomized, multicenter, double-blind, placebocontrolled trials in adults and adolescents 12 years of age and older with SAR. The similarly designed trials lasted two weeks and enrolled 2,352 patients. Assessment of efficacy was based on patient-reported reflective total nasal symptom score (rTNSS), along with other patient-reported measures of nasal and ocular symptoms. Across the two studies, treatment with Ryaltris resulted in statistically significant improvements in rTNSS compared to placebo.

Additionally, the filing includes data from a long-term safety study in 601 adults and adolescents 12 years of age and older with perennial allergic rhinitis (PAR). This trial was a three-arm, double-blind, randomized, parallel group, placebo-controlled safety study that randomized patients to 52 weeks of twice-daily treatment with Ryaltris, or two different formulations of a placebo nasal spray. The study also evaluated efficacy as a secondary endpoint, assessed as change from baseline in average morning patient-reported rTNSS. Ryaltris demonstrated a statistically significant and clinically meaningful improvement compared to placebo (p<0.0001) over 52 weeks of treatment.

The incidence of adverse reactions in four placebo-controlled clinical studies was 13.9% in the Ryaltris treatment groups versus 9.5% of patients in the placebo groups. The most frequently reported adverse reactions with Ryaltris greater than placebo was loss of taste sensitivity (3.0% vs. 0.3%, respectively), nosebleed (1.0% vs. 0.6%) and nasal discomfort (1.0% vs. 0.8%).

Shares of the company declined Rs 1.2, or 0.2%, to trade at Rs 588.15. The total volume of shares traded was 1,968 at the BSE (9.38 a.m., Wednesday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Lupin gets approval for Budesonide inhalation suspension - 13-Nov-2018 13:36
Suven Life Sciences secures 2 overseas product patents - 13-Nov-2018 10:18
GAIL Gas signs MoU with Energy Efficiency Services - 13-Nov-2018 10:14
Lupin launches generic Atovaquone oral suspension in US - 12-Nov-2018 16:06
Zydus Cadila gets USFDAs nod for anti-fungal ointment - 12-Nov-2018 13:40
NHB sanctions Rs 35 bn refinance facility to PNB Housing Finance - 12-Nov-2018 13:17
BHEL commissions 120 MW Pulichintala hydro-electric project - 12-Nov-2018 12:55
Tata Consultancy Services partners with ENGIE Laborelec - 12-Nov-2018 12:52
Lupin gets establishment inspection report for Nagpur unit - 12-Nov-2018 09:56
GAIL fast tracks North East feeder gas pipeline project - 12-Nov-2018 09:43
Biocon's new generic facility in Bengaluru completes inspection - 12-Nov-2018 09:35
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer